(19)
(11) EP 3 321 280 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.03.2021 Bulletin 2021/10

(45) Mention of the grant of the patent:
23.12.2020 Bulletin 2020/52

(21) Application number: 16198189.9

(22) Date of filing: 10.11.2016
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
C12N 15/113(2010.01)
 C07K 16/28(2006.01)
G01N 33/574(2006.01)

(54)

IMMUNE MODULATORS FOR REDUCING IMMUNE-RESISTANCE IN MELANOMA AND OTHER PROLIFERATIVE DISEASES

IMMUNMODULATOREN ZUR REDUZIERUNG DER IMMUNRESISTENZ IN MELANOMEN UND ANDEREN PROLIFERATIVEN ERKRANKUNGEN

MODULATEURS IMMUNITAIRES DE RÉDUCTION D'IMMUNO-RÉSISTANCE DANS UN MÉLANOME ET D'AUTRES MALADIES PROLIFERATIVES

(84) Designated Contracting States:
BE CH DE DK FR GB IE LI LU NL SE

(43) Date of publication of application:
16.05.2018 Bulletin 2018/20

(73) Proprietor: Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts
69120 Heidelberg (DE)

(72) Inventors:
  • Beckhove, Philipp
    93059 Regensburg (DE)
  • Michels, Tillmann
    93049 Regensburg (DE)
  • Khandelwal, Nisit
    80469 München (DE)
  • Boutros, Michael
    69117 Heidelberg (DE)
  • Breinig, Marco
    69198 Schriesheim (DE)
  • Sorrentino, Antonio
    93051 Regensburg (DE)
  • Volpin, Valentina
    93053 Regensburg (DE)

(74) Representative: Kuttenkeuler, David 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A1-2015/028515
WO-A2-2008/085601
 WO-A1-2015/121454
US-A1- 2013 130 379
   
  • Weizmann Institute of Science: "OR10H1", Weizmann Institute of Science , XP002769440, Retrieved from the Internet: URL:http://www.genecards.org/cgi-bin/cardd isp.pl?gene=OR10H1&keywords=or10h1 [retrieved on 2017-04-21]
  • TOPALIAN SUZANNE L ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443-2454, XP002767416, ISSN: 1533-4406
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).